Table 1.
Characteristics of Studies Included in the Network Meta-Analysis
| Study | Year | Region | Size | Interventions | Follow-up | Efficacy* |
|---|---|---|---|---|---|---|
| Elkind-Hirsch (15) | 2008 | USA | 14/14/14 | MET vs GLP-1 vs MET + GLP-1 | 24 weeks | 1, 2, 4, 8, 9 |
| Jensterle (16) | 2008 | Slovenia | 15/11 | MET vs TZDs | 24 weeks | 1, 2, 3, 5, 6, 7, 8, 9 |
| Jensterle (17) | 2014 | Slovenia | 14/11/11 | MET vs GLP-1 vs MET + GLP-1 | 12 weeks | 1, 2, 3, 5, 8, 9 |
| Jensterle (18) | 2015 | Slovenia | 14/14 | MET vs GLP-1 | 12 weeks | 1, 2, 3, 4, 5, 8, 9 |
| Jensterle (19) | 2015 | Slovenia | 13/14 | MET vs GLP-1 | 12 weeks | 2, 3, 4, 5, 6, 7, 8, 9 |
| Jensterle (20) | 2016 | Slovenia | 21/22 | GLP-1 vs MET + GLP-1 | 12 weeks | 2, 3, 4, 5, 6, 7, 8, 9 |
| Jensterle (21) | 2017 | Slovenia | 14/14 | GLP-1 vs MET + GLP-1 | 12 weeks | 2, 3, 4, 5, 6, 7, 8, 9 |
| Li (22) | 2017 | China | 39/39 | MET vs MET + TZDs | 12 weeks | 1, 2, 6, 7 |
| Liang (23) | 2019 | China | 22/21/23 | MET vs TZDs vs MET + TZDs | 12 weeks | 1, 2, 6, 7, 8 |
| Ortega-Gonzalez (24) | 2005 | Mexico | 18/17 | MET vs TZDs | 24 weeks | 3, 5, 6, 7, 8 |
| Shahebrahimi (25) | 2016 | Iran | 28/28 | MET vs TZDs | 12 weeks | 1, 2, 6, 7, 8, 9 |
| Steiner (26) | 2007 | Germany | 16/17 | MET vs TZDs | 24 weeks | 1, 6, 7, 8 |
| Wang (27) | 2014 | China | 41/40 | MET vs MET + TZDs | 24 weeks | 1, 2, 4, 6, 7, 8 |
| Yilmaz (28) | 2005 | Turkey | 20/20 | MET vs TZDs | 12 weeks | 1, 3, 5, 6, 7, 8, 9 |
Abbreviations: GLP-1, glucagon-like peptide-1 receptor agonist; MET, metformin; TZD, thiazolidinedione.
*Efficacy: 1, Menstrual frequency; 2, Total Testosterone (TT); 3, Free Testosterone (FT); 4, Sex hormone binding globulin (SHBG); 5, Androstenedione (AND); 6, Fasting glucose (FG); 7, Fasting insulin (FINS); 8, Body mass index (BMI); 9, Waist circumference (WC).